FDA Action Alert: Spectrum, ImmunoGen, Scynexis and Y-mAbs

cafead

Administrator
Staff member
  • cafead   Nov 21, 2022 at 10:22: AM
via The FDA has a number of PDUFA dates for the remainder of November for Spectrum's poziotinib in NSCLC, ImmunoGen's mirvetuximab soravtansine in ovarian cancer, Scynexis' Brexafemme in RVVC and more.

article source
 

<